keyword
MENU ▼
Read by QxMD icon Read
search

Ranibizumab

keyword
https://www.readbyqxmd.com/read/29240306/diabetic-macular-oedema-treated-with-intravitreal-anti-vascular-endothelial-growth-factor-2-4%C3%A2-years-follow-up-of-visual-acuity-and-retinal-thickness-in-566-patients-following-danish-national-guidelines
#1
Delila Hodzic-Hadzibegovic, Birgit Agnes Sander, Tine Juul Monberg, Michael Larsen, Henrik Lund-Andersen
PURPOSE: To investigate long-term functional and anatomical outcomes, discontinuation patterns, drug switching and rates of nonimprovement in patients treated with ranibizumab pro re nata (PRN) regimen for diabetic macular oedema (DME) according to the Danish national guidelines. METHODS: Retrospective cohort study of 566 eyes in 566 patients with centre-involved DME who started intravitreal treatment with ranibizumab between January 2011 and December 2013 in the Greater Copenhagen region...
December 14, 2017: Acta Ophthalmologica
https://www.readbyqxmd.com/read/29240298/diabetic-macular-edema-innovative-technologies-and-economic-impact-new-opportunities-for-the-lombardy-region-healthcare-system
#2
Emanuela Foglia, Lucrezia Ferrario, Francesco Bandello, Camilla Ferri, Innocente Figini, Michela Franzin, Gianpiera Gambaro, Ugo Introini, Massimo Medaglia, Giovanni Staurenghi, Patrizia Tadini, Andrea Fomiatti, Davide Croce
PURPOSE: Diabetic macular edema (DME) is a leading cause of vision loss and blindness. The aim of this study was to evaluate the economic benefits of introducing additional alternative technologies (Dexamethasone intravitreal implant - DEX - and Aflibercept injections), compared with the historical scenario of Ranibizumab intravitreal injections. METHODS: A 3-year budget impact model was developed, taking into consideration the perspective of the Lombardy Region Healthcare Service (LRHS)...
December 14, 2017: Acta Ophthalmologica
https://www.readbyqxmd.com/read/29232758/-time-course-of-changes-in-visual-acuity-after-a-single-injection-of-aflibercept-or-ranibizumab-in-neovascular-age-related-macular-degeneration-analysis-of-aggregated-real-life-data
#3
Robert G H Wilke, Robert Patrick Finger, Helmut G Sachs
Background Treatment of neovascular age-related macular degeneration (nvAMD) under real life conditions may differ from controlled prospective trials with respect to the number of injections and long term preservation of visual acuity. In many instances, intervals for controls and re-injection cannot be maintained as frequently as required. This case series examines actual intervals for control and re-injection visits, in order to estimate how prolonged intervals have an impact on momentary visual acuity and how long term visual outcome is affected...
December 2017: Klinische Monatsblätter Für Augenheilkunde
https://www.readbyqxmd.com/read/29232757/-real-life-data-on-the-treatment-of-diabetic-macular-oedema-in-germany
#4
Robert G H Wilke, Robert Patrick Finger, Helmut G Sachs
Background Controlled prospective clinical trials on the treatment of diabetic macular oedema (DME) using anti-VEGF compounds show very good results in visual acuity gain over several years. To date, only limited data are available from comparable studies under real-life settings in clinical routine. However, real-life data from other indications for anti-VEGF treatment suggest that, in clinical routine, gain in visual acuity is less pronounced and cannot be maintained over a longer period of time, which is related to the significantly lower number of injections administered in clinical routine...
December 2017: Klinische Monatsblätter Für Augenheilkunde
https://www.readbyqxmd.com/read/29232336/comparison-among-different-diagnostic-methods-in-the-study-of-type-and-activity-of-choroidal-neovascular-membranes-in-age-related-macular-degeneration
#5
Vittoria Ravera, Andrea Giani, Marco Pellegrini, Marta Oldani, Alessandro Invernizzi, Elisa Carini, Mario Cigada, Ferdinando Bottoni, Giovanni Staurenghi
PURPOSE: To determine interobserver and intraobserver agreement in classifying the subtypes of choroidal neovascularization (CNV) and the decision of retreatment in patients affected by exudative age-related macular degeneration. Different imaging techniques were evaluated individually and compared with multiimaging. METHODS: Fifty-two patients with naive CNV in age-related macular degeneration were evaluated after 3 monthly intravitreal injections of ranibizumab...
December 8, 2017: Retina
https://www.readbyqxmd.com/read/29217032/comparison-of-endophthalmitis-rates-following-intravitreal-injection-of-compounded-bevacizumab-ranibizumab-and-aflibercept
#6
Farzin Forooghian, David A Albiani, Andrew W Kirker, Andrew B Merkur
OBJECTIVE: Whereas the incidence of endophthalmitis after compounded intravitreal bevacizumab is known to be low, the rates of endophthalmitis after intravitreal injection of compounded ranibizumab and aflibercept are not known. The purpose of this study was to determine the incidence of endophthalmitis after treatment with compounded intravitreal ranibizumab and aflibercept and to compare this to the incidence with compounded intravitreal bevacizumab. DESIGN: Retrospective chart review...
December 2017: Canadian Journal of Ophthalmology. Journal Canadien D'ophtalmologie
https://www.readbyqxmd.com/read/29205853/comparative-study-of-in-situ-loaded-antibody-and-peg-fab-nipaam-gels
#7
Sahar Awwad, Athmar Al-Shohani, Peng T Khaw, Steve Brocchini
Hydrogels can potentially prolong the release of a therapeutic protein, especially to treat blinding conditions. One challenge is to ensure that the protein and hydrogel are intimately mixed by better protein entanglement within the hydrogel. N-isopropylacrylamide (NIPAAM) gels are optimized with poly(ethylene glycol) diacrylate (PEDGA) crosslinker in the presence of either bevacizumab or PEG conjugated ranibizumab (PEG10 -Fabrani ). The release profiles of the hydrogels are evaluated using an outflow model of the eye, which is previously validated for human clearance of proteins...
December 4, 2017: Macromolecular Bioscience
https://www.readbyqxmd.com/read/29204996/the-vegf-treatment-of-amd-switch-study-the-vtas-study
#8
Beverley Curry, Guy Bylsma, Alex W Hewitt, Nitin Verma
PURPOSE: To evaluate the effect of aflibercept on anatomic and visual outcomes in patients with choroidal neovascularization (CNV) previously treated with intravitreal ranibizumab with persistent fluid on optical coherence tomography (OCT). DESIGN: Prospective, open-label study. METHODS: Eighteen patients (19 eyes) with CNV being treated with monthly ranibizumab, with persistent fluid on OCT, were switched to intravitreal aflibercept injections at intervals of up to 8 weeks...
November 2017: Asia-Pacific Journal of Ophthalmology
https://www.readbyqxmd.com/read/29202760/injections-frequency-and-health-care-costs-in-patients-treated-with-aflibercept-compared-to-ranibizumab-new-real-life-evidence-from-switzerland
#9
Oliver Reich, Martin K Schmid, Roland Rapold, Lucas M Bachmann, Eva Blozik
BACKGROUND: Previous analyses of real-life data indicated that injection frequency and health care costs did not differ for anti-VEGF treatment with aflibercept and ranibizumab. The objective of this study was to investigate whether this finding persisted when analysing a longer time period after licensing. METHODS: Retrospective analysis of health insurance claims data of two large Swiss basic health insurance plans including 28% of the Swiss population. Patients qualified for inclusion if aflibercept or ranibizumab treatment had been initiated between June 1, 2013 and November 1, 2014...
December 4, 2017: BMC Ophthalmology
https://www.readbyqxmd.com/read/29201458/switch-to-aflibercept-in-the-treatment-of-neovascular-amd-long-term-results
#10
Pedro Neves Cardoso, Ana Fernanda Pinheiro, Jorge Meira, Ana Catarina Pedrosa, Manuel S Falcão, João Pinheiro-Costa, Fernando Falcão-Reis, Ângela M Carneiro
Purpose: To report the long-term clinical outcomes after switching from intravitreal bevacizumab or ranibizumab to aflibercept therapy in eyes with AMD. Methods: Retrospective analysis of changes in BCVA, SD-OCT image, and frequency of injections after 1, 2, and 3 years of follow-up. Results: 164 eyes were analyzed, 101 eyes switched from bevacizumab (group 1) and 63 from ranibizumab (group 2). One year after the switch, there was an overall nonsignificant mean decrease of 2 ETDRS letters in BCVA...
2017: Journal of Ophthalmology
https://www.readbyqxmd.com/read/29196745/characterization-of-liposomal-carriers-for-the-trans-scleral-transport-of-ranibizumab
#11
Rini Rachel Joseph, Dulcia Wei Ni Tan, Moreno Raja Miguel Ramon, Jayaganesh V Natarajan, Rupesh Agrawal, Tina T Wong, Subbu S Venkatraman
Age-related macular degeneration (AMD) is a leading cause of blindness in the modern world. The standard treatment regimen for neovascular AMD is the monthly/bimonthly intravitreal injection of anti-VEGF agents such as ranibizumab or aflibercept. However, these repeated invasive injections can lead to sight-threatening complications. Sustained delivery by encapsulation of the drug in carriers is a way to reduce the frequency of these injections. Liposomes are biocompatible, non-toxic vesicular nanocarriers, which can be used to encapsulate therapeutic agents to provide sustained release...
December 1, 2017: Scientific Reports
https://www.readbyqxmd.com/read/29190870/-recommendations-for-the-use-of-ranibizumab-in-diabetic-macular-edema-at-imss
#12
Roberto Ortiz-Lerma, Carlos Pedro González-Cervantes, Fabiola HernándezNúñez, Irene Ancona-Durán, Rodolfo Gregorio Barragán-Hervella, Gerardo López-Cázares, Isaac Betesh-Rodríguez, Noé Méndez, Daniel Garza-Cantú, Óscar López-Martínez, Adriana Marcela Martínez-Ruiz, Luis Miguel López-Montero, Armando Muñoz, Jorge Alberto Blancas-Ontiveros, Carlos Mariano Fernández-Trejo, Juan Carlos Mayorga-Rubalcava, Silvia Elizabeth Flores-Góngora, Jorge Luis Gómez-Galván, Patricia Armida Domínguez-Álvarez, Erik Sánchez-Hernández, Homero Cantú-Yeverinon
Diabetic macular edema can occur at any stage of diabetic retinopathy. It represents the main cause of vision loss in diabetes type I and II with a prevalence of 3-10% in diabetic patients of the Instituto Mexicano del Seguro Social (IMSS). Our aim is to elaborate treatment guidelines and provide recommendations for the use of intravitreal ranibizumab for diabetic medical edema at IMSS. Nine retina specialists and 10 ophthalmologists from IMSS high specialty medical units gathered to discuss the bibliographic evidence for the safety and efficacy of ranibizumab for this disease, in order to create consensus on its use in the institution...
November 2017: Revista Médica del Instituto Mexicano del Seguro Social
https://www.readbyqxmd.com/read/29190241/aflibercept-after-ranibizumab-intravitreal-injections-in-exudative-age-related-macular-degeneration-the-ari2-study
#13
Rocio Blanco-Garavito, Camille Jung, Joel Uzzan, Maddalena Quaranta-ElMaftouhi, Florence Coscas, Jose Sahel, Jean-Francois Korobelnik, Stéphane Béchet, Giuseppe Querques, Eric H Souied
PURPOSE: To analyze the efficacy of aflibercept switch treatment for regression of pigment epithelial detachment (PED) in patients previously treated with ranibizumab. METHODS: Multicenter, prospective, nonrandomized clinical trial. One eye of patients presenting neovascular age-related macular degeneration with PED of more than 250 μm in height, with persistent fluid, was included. Patients had to have received at least six ranibizumab intravitreal injections during the 12 months before enrollment...
November 22, 2017: Retina
https://www.readbyqxmd.com/read/29185099/real-life-clinical-data-for-dexamethasone-and-ranibizumab-in-the-treatment-of-branch-or-central-retinal-vein-occlusion-over-a-period-of-six-months
#14
Sibylle Winterhalter, Annabelle Eckert, Gerrit-Alexander Vom Brocke, Alice Schneider, Dominika Pohlmann, Daniel Pilger, Antonia M Joussen, Matus Rehak, Ulrike Grittner
PURPOSE: To evaluate the therapeutic outcome for dexamethasone implant (DEX) or intravitreal ranibizumab (IVR) injections over 6 months in patients with macular edema due to branch or central retinal vein occlusion (BRVO, CRVO), in a real-life setting. METHODS: A total of 107 patients with BRVO or CRVO were included into this retrospective single-center observational study. Patients were treated with monotherapy consisting of DEX or three monthly IVR injections following a pro re nata regimen (PRN)...
November 28, 2017: Graefe's Archive for Clinical and Experimental Ophthalmology
https://www.readbyqxmd.com/read/29184088/comparison-of-two-year-outcomes-after-photodynamic-therapy-with-ranibizumab-or-aflibercept-for-polypoidal-choroidal-vasculopathy
#15
Wataru Kikushima, Yoichi Sakurada, Atsushi Sugiyama, Seigo Yoneyama, Naohiko Tanabe, Mio Matsubara, Fumihiko Mabuchi, Hiroyuki Iijima
Photodynamic therapy (PDT) combined with intravitreal anti-vascular endothelial growth factor (VEGF) agents is currently the first-line treatment for polypoidal choroidal vasculopathy (PCV), along with anti-VEGF monotherapy. In this study, 100 eyes with treatment-naïve PCV were initially treated with PDT combined with intravitreal ranibizumab (IVR; n = 57) or aflibercept (IVA; n = 43). We compared two-year outcomes between these two groups and investigated factors associated with visual improvement and retreatment over 24 months...
November 28, 2017: Scientific Reports
https://www.readbyqxmd.com/read/29176524/novel-case-of-clostridium-perfringens-endophthalmitis-after-anti-vascular-endothelial-growth-factor-injection
#16
Varsha R Kadaba, Jayshree Menon
INTRODUCTION: Endophthalmitis after anti-vascular endothelial growth factor injection is a rare complication but may lead to rapid destruction of structures within the eye. Infection with Clostridium perfringens has not previously been reported in this context. CASE REPORT: A 90-year-old woman presented with endophthalmitis of the right eye, 2 days after an intravitreal injection of ranibizumab. Initial examination showed a high intraocular pressure, refractive to topical treatment, reduced vision, and a hypopyon...
November 22, 2017: Retinal Cases & Brief Reports
https://www.readbyqxmd.com/read/29166140/comparison-of-short-term-choroidal-thickness-and-retinal-morphological-changes-after-intravitreal-anti-vegf-therapy-with-ranibizumab-or-aflibercept-in-treatment-naive-eyes
#17
Magda Gharbiya, Rosalia Giustolisi, Jessica Marchiori, Alice Bruscolini, Fabiana Mallone, Valeria Fameli, Marcella Nebbioso, Solmaz Abdolrahimzadeh
PURPOSE: To evaluate choroidal thickness (CT) and retinal morphological changes in eyes with neovascular age-related macular degeneration (nAMD) following ranibizumab or aflibercept intravitreal treatment. MATERIALS AND METHODS: This was a prospective, observational, comparative study where 76 eyes of 76 consecutive patients with treatment-naive nAMD were consecutively enrolled and randomized to ranibizumab 0.5 mg or aflibercept 2 mg injections. Spectral-domain optical coherence tomography images of the choroid were obtained by enhanced depth imaging modality...
November 22, 2017: Current Eye Research
https://www.readbyqxmd.com/read/29164480/dispensing-patterns-of-ranibizumab-and-aflibercept-for-the-treatment-of-neovascular-age-related-macular-degeneration-a-retrospective-cohort-study-in-australia
#18
Adrian Skelly, Hans-Joachim Carius, Vladimir Bezlyak, Fred K Chen
INTRODUCTION: Anti-vascular endothelial growth factor therapy is the standard of care for neovascular age-related macular degeneration (nAMD). The dosage of two licensed agents, ranibizumab and aflibercept, was established through clinical trials; however, it is unclear if either agent is administered as recommended in routine clinical practice. Using pharmacy claims data, we investigated if the dispensing patterns of ranibizumab differ from those of aflibercept 6 and 12 months after treatment initiation...
November 21, 2017: Advances in Therapy
https://www.readbyqxmd.com/read/29160779/outcome-of-intravitreal-aflibercept-for-refractory-pigment-epithelial-detachment-with-or-without-subretinal-fluid-and-secondary-to-age-related-macular-degeneration
#19
Kiyoung Kim, Eung Suk Kim, Yonguk Kim, Ji Ho Yang, Seung-Young Yu, Hyung Woo Kwak
PURPOSE: To investigate the outcomes of intravitreal aflibercept in refractory pigment epithelial detachment (PED) with or without subretinal fluid (SRF) in patients with neovascular age-related macular degeneration. METHODS: A prospective, nonrandomized, interventional case series involved 40 patients with persistent vascularized PED previously treated with at least 3 injections of intravitreal bevacizumab or ranibizumab. Intravitreal aflibercept was administered as 3 initial loading doses every 4 weeks, followed by pro re nata retreatment every 8 weeks over 48 weeks...
November 16, 2017: Retina
https://www.readbyqxmd.com/read/29148027/sequential-tissue-plasminogen-activator-pneumatic-displacement-and-anti-vegf-treatment-for-submacular-hemorrhage
#20
Handan Bardak, Yavuz Bardak, Yeşim Erçalık, Burak Erdem, Gökhan Arslan, Semrin Timlioglu
PURPOSE: To report the results of our sequential intravitreal (IV) tissue plasminogen activator (tPA), pneumatic displacement (PD), and IV anti-vascular endothelial growth factor (VEGF) treatment in patients with neovascular age-related macular degeneration (nAMD)-related submacular hemorrhage (SMH). METHODS: A total of 16 eyes of 16 patients with SMH of less than 15 days duration were included in this retrospective pilot study. The tPA was applied on the day of diagnosis, and PD was performed the following day...
November 4, 2017: European Journal of Ophthalmology
keyword
keyword
1767
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"